Cargando…
Is there transparency in the pricing of medicines in the South African private sector?
Recent investigations by the Competition Commission of South Africa (SA) of suspected excessive pricing of cancer medicines in SA by three global pharmaceutical companies have once again drawn attention to increasing medicine pricing transparency and warrant further public debate.
Autores principales: | Bangalee, V, Suleman, F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989011/ https://www.ncbi.nlm.nih.gov/pubmed/29429435 |
Ejemplares similares
-
Assessing the prices and affordability of oncology medicines for three common cancers within the private sector of South Africa
por: Mattila, Phyllis Ocran, et al.
Publicado: (2021) -
Affordability of essential medicine prices in Malaysia’s private health sector
por: Ahmad, Nur Sufiza, et al.
Publicado: (2018) -
Happiness among South African private sector physiotherapists
por: Elliot, Michael, et al.
Publicado: (2018) -
Association between medicine Price declaration by pharmaceutical industries and retail prices in Malaysia’s private healthcare sector
por: Ahmad, Nur Sufiza, et al.
Publicado: (2019) -
Prices of combination medicines and single‐molecule antihypertensive medicines in India's private health care sector
por: Negi, Sagri, et al.
Publicado: (2020)